DelMar Pharmaceuticals Inc  

(Public, OTCMKTS:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
0.000 (0.00%)
Oct 6 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.43 - 1.02
Open     -
Vol / Avg. 0.00/58,942.00
Mkt cap 30.60M
P/E     -
Div/yield     -
EPS -0.13
Shares 39.48M
Beta     -
Inst. own 0%
Sep 9, 2015
DelMar Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 4, 2015
Full Year 2015 DelMar Pharmaceuticals Inc Earnings Call
Sep 4, 2015
Q4 2015 DelMar Pharmaceuticals Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -100.17% -126.56%
Return on average equity -511.89% -861.17%
Employees 4 -
CDP Score - -


999 Broadway W Suite 720
+1-604-6295989 (Phone)

Website links


DelMar Pharmaceuticals, Inc. formerly Berry Only Inc., is developing new drug candidates targeting orphan cancer indications. The Company’s product development programs VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer. The Company has opened an Investigational New Drug (IND) with the United States Food & Drug Administration (FDA) to begin Phase II human clinical trials with VAL-083 in patients suffering from glioblastoma multiforme (GBM). Glioblastoma multiforme (GBM) is the common and malignant form of brain cancer.

Officers and directors

Jeffrey A. Bacha President, Chief Executive Officer, Director
Age: 47
Scott Praill Chief Financial Officer
Age: 49
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 65
William J. Garner M.D. Director
Age: 48
Robert J. Toth Jr Director
Age: 51
John K. Bell Independent Director
Age: 67
Lynda Sarah Cranston Independent Director
Age: 67
Erich Mohr Ph.D. Independent Director
Age: 60